课题基金 / 基金详情

PHASE I PHARMACOKINETIC STUDY OF BCH 4556

PHASE I PHARMACOKINETIC STUDY OF BCH 4556
BCH 4556 的 I 期药代动力学研究
批准号：
6586837
负责人：
ERIC K ROWINSKY
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
项目状态：
已结题
起止时间：
2001-12-01 至 2002-11-30
来源：
https://reporter.nih.gov/project-details/6586837
关键词：
antineoplastics clinical research clinical trial phase I dosage drug screening /evaluation human subject human therapy evaluation injection /infusion neoplasm /cancer chemotherapy pharmacokinetics

项目摘要

项目成果

ERIC K ROWINSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary objective of this study is to determine the maximum tolerated dose of BCH 4556, one of a category of compounds called L-enantiomers. The drug will be infused over 30 minutes for five consecutive days every three weeks. Quantitative and qualitative toxicities and their reversibility will be determined and the pharmacokinetic behavior of the drug will be described.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph I Study Of BMS-247550 In PTS with advanced Neoplasms
Phase II Pharmacologic/Biologic Study of Thalidomide
Ph I Pharmacokinetics of NSC-655649/Cisplatin/G-CSF
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION
海外基金